Orange Book product · Generic (ANDA)
OLANZAPINE
OLANZAPINE
At a glance
Mar 05, 2026
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 05, 2026
4 mo ago
Today
Pharmaceutical detail
Active ingredient
OLANZAPINE
Strength
10MG/VIAL
Dosage form
POWDER
Route
INTRAMUSCULAR
TE code
AP
Application
ANDA 220323
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of OLANZAPINE
- 2004ZYPREXABrand (NDA)
NDA 021253 · CHEPLAPHARM
- 2000ZYPREXA ZYDISBrand (NDA)
NDA 021086 · CHEPLAPHARM
- 1996ZYPREXABrand (NDA)
NDA 020592 · CHEPLAPHARM
- 2026OLANZAPINEGeneric (ANDA)
ANDA 219048 · OMNIVIUM PHARMS
- 2025OLANZAPINEGeneric (ANDA)
ANDA 211072 · UBI
- 2025OLANZAPINEGeneric (ANDA)
ANDA 218116 · QILU
- 2023OLANZAPINEGeneric (ANDA)
ANDA 217466 · ASPIRO
- 2023OLANZAPINEGeneric (ANDA)
ANDA 202889 · ZYDUS PHARMS
- 2023OLANZAPINEGeneric (ANDA)
ANDA 210022 · CADILA PHARMS LTD
- 2020OLANZAPINEGeneric (ANDA)
ANDA 206892 · HISUN PHARM HANGZHOU
- 2020OLANZAPINEGeneric (ANDA)
ANDA 206924 · HISUN PHARM HANGZHOU
- 2020OLANZAPINEGeneric (ANDA)
ANDA 210968 · EUGIA PHARMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
